Grünenthal completed the acquisition of Mestex.

Grünenthal, a pharmaceutical company headquartered in Aachen, completed the acquisition of Mestex, a Swiss biotech company. Financial terms were not disclosed. "Osteoarthritis is a progressive condition that currently cannot be cured. The inflamed, swollen and painful joints lead to limitation on mobility of the affected patients and may impact their quality of life significantly. Millions of patients currently receive intra-articular corticosteroids or need to undergo knee replacement surgery as last remaining treatment option," Jan Adams, Grünenthal Chief Scientific Officer.